Why Tonix Pharmaceuticals Stock Is Soaring Today
Shares of clinical-stage biopharmaceutical company Tonix Pharmaceuticals Holding (NASDAQ: TNXP) are rising sharply on Wednesday following the company's release of data from a study for its experimental COVID-19 vaccine TNX-1800. Tonix Pharmaceuticals' stock was up by 17.3% as of 2:07 p.m. EDT today, after jumping by as much as 25.2% earlier in the day.
The study in question pitted TNX-1800 against a control vaccine called TNX-801 in nonhuman primates divided into five groups of four: Two groups received the TNX-1800 at two different doses, two more groups received RNX-801 at two doses, and the last group received a placebo.
Then, 41 days after vaccination, each group was exposed to the virus that causes COVID-19 through intratracheal and intranasal administration. Six days later (at day 47 after vaccination), none of the eight animals vaccinated with TNX-1800 (at either dose) showed infection with the virus.
Source Fool.com
